EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Open Access · CC BY 4.0

Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer

Changhee Park, Koung Jin Suh, Se Hyun Kim, Kyung-Hun Lee, Seock-Ah Im, Min Hwan Kim, Joohyuk Sohn, Jae Ho Jeong, Kyung Hae Jung, Kyoung Eun Lee, Yeon Hee Park, Hee-Jun Kim und 6 weitere

Cancer Immunology, Immunotherapy · 2024

DOI: 10.1007/s00262-024-03782-7 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Changhee Park und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, 82, Gumi-Ro, Bundang-Gu, Seongnam, 1362…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Furans, Ketones. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIEHS NIH HHS, Seoul National University Bundang Hospital, Ministry of Health and Welfare, Republic of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biomarkers for predicting response to the immunotherapy and chemotherapy combination in breast cancer patients are not established. In this study, we report exploratory genomic and transcriptomic analyses of pretreatment tumor tissues from patients enrolled in phase II clinical trial of a combination of eribulin and nivolumab for HER-2-negative metastatic breast cancer (MBC) (KORNELIA trial, NCT04061863).

Methods

We analyzed associations between tumor molecular profiles based on genomic ( n = 76) and transcriptomic data ( n = 58) and therapeutic efficacy. Patients who achieved progression-free survival (PFS) ≥ 6 months were defined as PFS6-responders and PFS6-nonresponders otherwise.

Findings

Analyses on tumor mutation burden (TMB) showed a tendency toward a favorable effect on efficacy, while several analyses related to homologous recombination deficiency (HRD) indicated a potentially negative impact on efficacy. Patients harboring TP53 mutations showed significantly poor PFS6 rate and PFS, which correlated with the enrichment of cell cycle-related signatures in PFS6-nonresponders. High antigen presentation gene set enrichment scores (≥ median) were significantly associated with longer PFS. Naïve B-cell and plasma cell proportions were considerably higher in long responders (≥ 18 months).

Interpretation

Genomic features including TMB, HRD, and TP53 mutations and transcriptomic features related to immune cell profiles and cell cycle may distinguish responders. Our findings provide insights for further exploring the combination regimen and its biomarkers in these tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsFuransKetonesNivolumabErb-b2 Receptor Tyrosine KinasesTranscriptomeAdultAgedFemaleHumansMiddle AgedBiomarkers, TumorGene Expression ProfilingGenomicsMutationNeoplasm MetastasisPolyether Polyketides

Stichwörter der Autor:innen

BiomarkerEribulinGenomicsHER-2-negative metastatic breast cancerImmunotherapyTranscriptomics

Substanzen

Biomarkers, TumorFuransKetonesNivolumabPolyether PolyketidesErb-b2 Receptor Tyrosine KinasesERBB2 protein, humaneribulin

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, 82, Gumi-Ro, Bundang-Gu, Seongnam, 13620, Republic of Korea.
  • Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, 82, Gumi-Ro, Bundang-Gu, Seongnam, 13620, Republic of Korea. sehyunkim@snubh.org.
  • Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University, College of Medicine, Seoul, Republic of Korea.
  • Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Hematology and Oncology, Ewha Womans University Hospital, Seoul, Korea.

Förderung

  • NIEHS NIH HHS
  • Seoul National University Bundang Hospital
  • Ministry of Health and Welfare, Republic of Korea

Zitieren

APA

Park, C., Suh, K. J., Kim, S. H., Lee, K. H., Im, S. A., Kim, M. H., Sohn, J., Jeong, J. H., Jung, K. H., Lee, K. E., Park, Y. H., Kim, H. J., Cho, E. K., Choi, I. S., Noh, S. J., Shin, I., Cho, D. Y., & Kim, J. H. (2024). Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03782-7

Vancouver

Park C, Suh KJ, Kim SH, Lee KH, Im SA, Kim MH, et al. Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03782-7

BibTeX
@article{Park2024,
  author = {Park, Changhee and Suh, Koung Jin and Kim, Se Hyun and Lee, Kyung-Hun and Im, Seock-Ah and Kim, Min Hwan and Sohn, Joohyuk and Jeong, Jae Ho and Jung, Kyung Hae and Lee, Kyoung Eun and Park, Yeon Hee and Kim, Hee-Jun and Cho, Eun Kyung and Choi, In Sil and Noh, Seung-Jae and Shin, Inkyung and Cho, Dae-Yeon and Kim, Jee Hyun},
  title = {Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  doi = {10.1007/s00262-024-03782-7}
}
Kostenlos starten →